NYRADA INC. (ASX:NYR) 8 CEO Report Dear Fellow CDI Holders, It is with great pride that I report on Nyrada's progress over the 2026 financial year, a year in which the Company translated the clinical and scientific groundwork of prior periods into tangible momentum. Twelve months ago, we had just completed dosing in our first-in-human Phase I study. Today, Xolatryp® is being administered to patients in a Phase IIa clinical trial, and our TRPC platform has extended its reach into oncology. This has been, by any measure, a transformative year. Completing Phase I Early in the financial year, we released the full, unblinded results from our Phase I clinical trial in healthy volunteers. The Safety Review Committee’s review of the final cohort identified no dose-limiting safety signals in participants who received Xolatryp, and the complete dataset confirmed that Xolatryp was well tolerated, with no serious adverse events observed. Adverse events occurred in both the placebo and Xolatryp arms and were classified as either mild or moderate. Pharmacokinetic analysis showed predictable, linear blood levels over time, with no differences in exposure between sexes. Together, these results provided the confidence and regulatory basis to advance clinical development into a Phase IIa study. Launching PROTECT-MI, our Phase IIa Trial A key milestone in FY2026 was the design and launch of PROTECT-MI, our Phase IIa clinical trial. The study is evaluating Xolatryp in heart attack patients undergoing angioplasty with stenting, known as PCI. While safety is the primary endpoint, the trial is also assessing secondary and exploratory measures of efficacy, including cardiac function, the extent of cardiac injury, troponin I biomarkers, and arrhythmia incidence. As the trial is randomised, double-blind, and placebo-controlled, efficacy data will remain blinded until completion. In the meantime, we will continue to update the market on recruitment progress and independent Safety Review Committee assessments. During the year, we established the infrastructure needed to support a well-run clinical trial. This included appointing Accelagen as our Contract Research Organisation, confirming Professor William Chan as Coordinating Principal Investigator, securing Human Research Ethics Committee approval, and advancing research governance approvals across selected Australian sites. “Twelve months ago, we had just completed dosing in our first-in-human Phase I study. Today, Xolatryp® is being administered to patients in a Phase IIa clinical trial, and our TRPC platform has extended its reach into oncology.”
RkJQdWJsaXNoZXIy MjE2NDg3